1. Home
  2. MDAI vs PDSB Comparison

MDAI vs PDSB Comparison

Compare MDAI & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MDAI

Spectral AI Inc.

HOLD

Current Price

$1.71

Market Cap

60.1M

Sector

Health Care

ML Signal

HOLD

Logo PDS Biotechnology Corporation

PDSB

PDS Biotechnology Corporation

HOLD

Current Price

$0.88

Market Cap

62.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MDAI
PDSB
Founded
2013
2005
Country
United States
United States
Employees
65
10
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
60.1M
62.0M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
MDAI
PDSB
Price
$1.71
$0.88
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$3.00
$9.00
AVG Volume (30 Days)
494.6K
858.3K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
28.16
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$23.50
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.18
$0.51
52 Week High
$3.21
$1.55

Technical Indicators

Market Signals
Indicator
MDAI
PDSB
Relative Strength Index (RSI) 36.96 40.70
Support Level $1.48 $0.88
Resistance Level $1.77 $1.12
Average True Range (ATR) 0.09 0.10
MACD -0.02 -0.02
Stochastic Oscillator 27.14 8.76

Price Performance

Historical Comparison
MDAI
PDSB

About MDAI Spectral AI Inc.

Spectral AI Inc is an AI company focused on predictive medical diagnostics. Its DeepView System uses proprietary AI algorithms to distinguish between fully damaged, partially damaged and healthy human tissue characters invisible to the naked eye, at the initial time point of wound presentation. The DeepView System delivers a binary prediction on the wound's capacity to heal or not-heal by a specified time point in the future. The company focuses on the burn indication which is supported by the BARDA PBS contract.

About PDSB PDS Biotechnology Corporation

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.

Share on Social Networks: